At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
This study will compare the effects of different amounts of aerobic exercise on heart and lung (cardiorespiratory) fitness in post-menopausal women who completed treatment for early-stage breast cancer. Researchers will study the effects of different exercise programs on oxygen use, heart pumping ability, lung function, and blood vessel health. Participants will be randomly assigned to one of four groups:
- A Phase 2 Study of Belumosudil After a Stem Cell Transplant to Prevent Graft-Versus-Host Disease
Full Title Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation
Purpose
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor’s healthy immune cells see the recipient’s normal cells as foreign and begin to attack them.
GVHD can affect many parts of the body, including the skin, liver, stomach, intestines, joints, eyes, mouth, and lungs. It can range from mild to severe and is a common cause of reduced quality of life after a transplant.
This study aims to find out whether giving belumosudil, in addition to standard immunosuppressive therapy, can reduce GVHD risk. Belumosudil is an oral medication that works by blocking specific proteins that control immune system activity. By keeping the immune system in balance, belumosudil may help prevent GVHD. It will be given around day 100 after the transplant
If you take part in this study, you will get belumosudil as well as the usual treatment to prevent GVHD. This treatment includes tacrolimus with or without cyclophosphamide chemotherapy. Your doctor will let you know whether or not you will get cyclophosphamide.
Who Can Join
To join this study, there are a few conditions. You must:
- Have had an allogeneic stem cell transplant (from a donor) for blood cancer and received cyclophosphamide or abatacept treatment to prevent GVHD.
- Have received your stem cell transplant no more than 4 months before entering the study.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.
Protocol
25-033Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07006506ClinicalTrials.gov
-
Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.
-
People with early-stage breast cancer who undergo lumpectomy have traditionally also received radiation therapy and hormonal (endocrine) therapy to reduce their risk of breast cancer recurrence. Doctors want to know if some patients with low-risk early-stage breast cancer can forgo radiation therapy (which takes several weeks and has side effects) and do as well if they receive only hormonal therapy after lumpectomy.
-
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
-
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
-
Researchers want to find the best dose of BH-30236 to treat people with leukemia. This study includes people with acute myelogenous leukemia (AML) that relapsed (came back) after treatment. It also includes people with higher-risk myelodysplastic syndrome (MDS). Higher-risk means a disease has a higher chance of coming back or not responding to standard treatment.
-
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
-
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
-
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.